ClinicalTrials.gg
CompletedNCT00237172Updated May 1, 2012

Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)

A Phase 2 interventional study of Imatinib Mesylate in Gastrointestinal Stromal Tumors, sponsored by Novartis Pharmaceuticals. Completed. Open to participants aged 20 Years to 74 Years. Per ClinicalTrials.gov, last updated 2012-05-01.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
72
Allocation
Not applicable
Ages
20 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing imatinib in Gastrointestinal Stromal Tumors — 8 open to participants now, 9 under way, 2 of them phase 3. imatinib · Gastrointestinal Stromal Tumors.

Enrollment
21st of 50
72 · median 56
Started
2002
with 4 others
Phase 2
25 of 50
5 open now
Registered
13th of 50
by date
Lead sponsor
10 of 50
Novartis Pharmaceuticals

Among the 50 studies testing imatinib in Gastrointestinal Stromal Tumors, this one is the 21st largest by enrollment, is one of 5 that started in 2002, is one of 25 in phase 2, and was the 13th registered.

Gastrointestinal Stromal Tumors

343 studies on the registry are indexed under Gastrointestinal Stromal Tumors; 61 are open to participants now.

Browse Gastrointestinal Stromal Tumors studies →

Open to participants now

8 of the 50 studies testing imatinib in Gastrointestinal Stromal Tumors are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About imatinib

imatinib: first FDA approval 2001 (GLEEVEC), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 49 Gastrointestinal Stromal Tumors studies recruiting now, 38 (78%) set no upper age limit and 4 (8%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 20 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing imatinib in Gastrointestinal Stromal Tumors, or all of them as a file.
02

Study summary

This is a extension study of CSTI571B1201 study

03

Conditions studied

  • Gastrointestinal Stromal Tumors

Keywords

  • GIST
  • Imatinib
  • STI571
  • Gastrointestinal Stromal Tumors
04

Who can participate

Ages eligible
20 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who completed the CSTI571B1201 study

Exclusion criteria

Exclusion Criteria:

-

Other protocol-defined inclusion / exclusion criteria may apply.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Imatinib Mesylate

    400 mg once daily

    Drug: Imatinib Mesylate

Interventions

06

What researchers measure

Primary outcomes

  1. To study the antineoplastic effect of the investigational drug.

Secondary outcomes

  1. To study the safety and pharmacokinetics of the investigational drug.

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2002 and a primary completion of Jul 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2005
First posted
Oct 12, 2005
Start
Sep 2002
Primary completionActual
Jul 2005
Last update
May 1, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00237172
Responsible party
Sponsor
First posted
Oct 12, 2005
Start date
Sep 2002
Primary completion
Jul 2005
Last update
May 1, 2012

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Imatinib

Start the discussion